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effective drug combinations has been of 
interest for a long time, and the discov-
ered drug combinations have been applied 
to cure patients with resistant cancers 
that were difficult to treat with single-
drug therapy.[2,3] However, the concurrent 
administration of multiple drugs increases 
dose exposure in patients at a specific 
moment and, therefore, has significant 
potential to result in side effects.[4,5] To 
address this limitation, sequential treat-
ment with multiple drugs has received 
much attention.[6,7] Recently, several 
studies have reported the sequence-
dependency of some drug combinations, 
which is more powerful than concurrent 
combinations.[8–11] The underlying prin-
ciple is the dynamic rewiring of intracel-
lular pathways in which the pretreated 
drug makes the cell status vulnerable to the 
post-treatment drug.[12,13] If such an effec-
tive sequential combination can be found 
for each patient, thus resulting in person-
alized medicine, it can provide not only a 
promising therapeutic effect but also help 
to improve the quality of life by reducing 
the drug dose given to the patient.[4,5]
Finding effective drug combinations for a patient gene-
rally requires unbiased large-scale screening.[14,15] However, 
the number of cells obtained from a patient is usually limited; 
thus, only a few combinations can be tested for cell samples by 
Large-scale screening of sequential drug combinations, wherein the dynamic 
rewiring of intracellular pathways leads to promising therapeutic effects and 
improvements in quality of life, is essential for personalized medicine to 
ensure realistic cost and time requirements and less sample consumption. 
However, the large-scale screening requires expensive and complicated liquid 
handling systems for automation and therefore lowers the accessibility to 
clinicians or biologists, limiting the full potential of sequential drug combina-
tions in clinical applications and academic investigations. Here, a miniaturized 
platform for high-throughput combinatorial drug screening that is “pipetting-
free” and scalable for the screening of sequential drug combinations is pre-
sented. The platform uses parallel and bottom-up formation of a heterogeneous 
drug-releasing hydrogel microarray by self-assembly of drug-laden hydrogel 
microparticles. This approach eliminates the need for liquid handling systems 
and time-consuming operation in high-throughput large-scale screening. In 
addition, the serial replacement of the drug-releasing microarray-on-a-chip 
facilitates different drug exchange in each and every microwell in a simple and 
highly parallel manner, supporting scalable implementation of multistep com-
binatorial screening. The proposed strategy can be applied to various forms of 
combinatorial drug screening with limited amounts of samples and resources, 
which will broaden the use of the large-scale screening for precision medicine.
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1. Introduction
Treating diseases with multiple drugs leads to more complex 
and elaborate cellular pathway regulation.[1] Thus, finding 
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using conventional high-throughput screening (HTS) platforms 
(i.e., 96- or 384-well-plate-based platforms).[16,17] To overcome 
this limitation, various types of HTS platforms have evolved to 
reduce the reaction volume, thereby decreasing the consump-
tion of valuable cells and reagents.[18–21] These platforms only 
need nanoliter or picoliter amounts of reagents and a few hun-
dred cells per reaction, thus making large-scale drug screening 
with patient-derived samples possible.[16,17] However, as the 
screening platform becomes miniaturized and the scale of 
screening expands, increasingly sophisticated and expensive 
liquid handling systems are required for managing the large 
number of drug candidates to be tested.[22] Because the majority 
of hospitals and laboratories worldwide have difficulty securing 
proper infrastructure and extra funding to operate such a high-
cost liquid handling system, it is challenging for them to utilize 
HTS for clinical applications and academic studies.[16,17]
This study aimed to provide an affordable screening tool for 
performing sequential drug screening with a reduced workload 
and sample requirement. To achieve this goal, we developed a 
miniaturized “pipetting-free” HTS platform for sequential com-
binatorial screening with high scalability (Figure 1). There are 
multiple advantages to our platform. First, the cost of HTS sig-
nificantly decreases because this platform eliminates the need 
for an expensive liquid handling system, which accounts for 
the majority of the cost of implementing HTS. We developed a 
bottom-up formation method of heterogeneous drug microarray 
that was formed by the self-assembly of encoded drug-laden 
microparticles (DLPs) on a microwell array (Figure 1b). This 
scalable method requires just one-step pipetting to provide a 
large-scale drug-releasing microarray-on-a-chip. Several 
previous studies have attempted to achieve pipetting-free HTS 
platforms, but these techniques were limited to preparing a 
homogeneous microarray (i.e., cell microarray).[23–25] Second, the 
simple and robust implementation of multistep (or sequential) 
drug treatment is enabled by serially replacing drug-releasing 
microarrays combined with a cell microarray (Figure 1a). Our 
technique is easily scalable for large-scale, sequential combi-
natorial screening in particular because only the n-step pipet-
ting operation, instead of the exponentially increasing liquid 
handling operations, is sufficient for n-step drug combina-
tion screening. We demonstrated a sequential combinatorial 
screening of a targeted inhibitor followed by genotoxin against 
triple-negative breast cancer (TNBC), which is known to be an 
especially highly resistant form of breast cancer. As a result, 
we found that erlotinib followed by mitoxantrone showed the 
most promising effect among tested combinations and inves-
tigated their synergism from the dose–response matrix. To 
our best knowledge, this pair had not been discovered prior to 
our study. We believe that our proposed technique can narrow 
the gap between HTS and individual laboratories with limited 
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Figure 1. Large-scale sequential combination screening by serial replacement of a drug-releasing hydrogel microarray-on-a-chip. a) Principle of rewiring 
cellular pathways by effective sequential drug treatment, and schematic illustration of multistep drug treatment in a highly parallel manner to find an 
efficient sequential drug pair. The drug-releasing hydrogel microarray-on-a-chip is combined with the cell chip to facilitate the multiplexed bioassay. 
Simple exchange of the microarray-on-a-chip enables sequential delivery of heterogeneous drug combinations to corresponding microwells in a parallel 
manner. b) Schematic illustration of how the large-scale, drug-releasing hydrogel microarray-on-a-chip is constructed by fully manual operation with a 
reduced workload. (i) Encoded drug-laden microparticles (DLPs) are moved from the library to the assembly chip by one-step pipetting. (ii) Encoded 
DLPs are simply assembled into microwells on the assembly chip by scraper-assisted directed assembly. (iii) Array of DLPs is transferred to the transfer 
chip by stamping. (iv) Codes of encoded DLP are decoded automatically to identify which drug treatment was applied to each microwell.
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resources, thereby expanding the application of HTS in various 
fields. We envision that our platform can contribute especially 
to finding efficient drug combinations for each patient and 
accelerate the era of personalized medicine.
2. Results
2.1. Preparation of Drug-Releasing Hydrogel 
Microarray-on-a-Chip
The preparation of a drug-releasing hydrogel microarray-on-
a-chip is conducted by “partipetting,” a word that represents 
a combination of the words “particles” and “pipetting.”[26,27] 
This word indicates the delivery of heterogeneous DLPs with 
single pipetting and the directed self-assembly of DLPs into 
microwells of an “assembly chip” (Figure 1b-i,ii). With the par-
tipetting method, thousands of heterogeneous drugs can be 
delivered simultaneously; thus, one-step pipetting is required 
for one chip. Subsequently, assembled DLPs are transferred 
to a “transfer chip,” which has a thin PDMS layer on a poly-
styrene chip, thereby constructing a drug-releasing hydrogel 
microarray-on-a-chip (Figure 1b-iii). Because DLPs are ran-
domly assembled during partipetting, a code-reading process 
is implemented to identify which drug is delivered to which 
microwell (Figure 1b-iv). A DLP code indicates the drug with 
which a microparticle is impregnated.
2.2. Validation of Partipetting Platform for Multiplexed  
Cell-Based Assay
Encoded hydrogel microparticles, which are used as drug car-
riers, were fabricated by photolithography with a photocur-
able polymer (polyethylene glycol diacrylate, Mn = 700). These 
particles have a diameter of 138 µm and a thickness of 38 µm. 
Polymerized hydrogels were washed with ethanol two times 
to remove the uncured monomer and were easily collected 
into the test tube or well plate by using a blade (Figure S1a, 
Supporting Information). No cytotoxicity caused by hydrogel 
microparticles was found (Figure S1b, Supporting Informa-
tion). A library of drug-laden hydrogel microparticles could 
be prepared in a simple and highly parallel manner, which is 
described as follows (Figure S1c, Supporting Information). The 
drug solution was added into the microwells with prefabricated 
microparticles, and the solvent was removed by freeze-drying. 
Because commercial drug libraries are generally supplied in 
a 96- or 384-well plate format and microparticles can also be 
supplied in a well plate format, the DLPs-supplier or the end-
user only needs to transfer the drug solution and freeze-dry the 
mixture. After they were completely dried, the microparticles in 
each microwell were collected into inert silicone oil to construct 
a DLP library. Here, silicone oil prevents cross-contamination 
between different DLPs[26] and functions to deliver liquid 
during the partipetting process. Most of the silicone oil that 
remains after the assembly process was removed, and then the 
array of DLPs was transferred to the transfer chip. Thus, there 
was no residual silicone oil to disturb the release of the drug or 
change the culture condition.
As opposed to our previous study on the partipetting plat-
form,[26] we adopted the freeze-drying-based drug-loading 
method in this study to attain a uniform and high amount of 
drug loading regardless of the drug or solvent type.[28] With 
rhodamine-B as a model substance, we investigated the loading 
uniformity by measuring the fluorescence intensity of the 
microparticles (Figure 2a, and Figure S2, Supporting Informa-
tion). The loading uniformity from the previous method (gray) 
was 30.6% and was improved 6.19% by freeze-drying (red). The 
number of drug molecules that could be delivered to a micro-
well with a single microparticle could be estimated from a 
bulk-scale loading–releasing experiment (Figure 2b, Figure S3, 
Supporting Information, and the Experimental Section). After 
drug loading, 1.5 mL phosphate-buffered saline (PBS) solution 
was added to the DLPs, and then the mixture was shaken on a 
mixing block overnight, which was enough time for complete 
release (Figure 2b-i). We set the volume of the PBS solution 
to make the particle number (15225) to the releasing volume 
(1.5 mL) ratio equivalent to the ratio of a single particle to the 
volume of one microwell on the cell chip (100 nL) (Table S2, 
Supporting Information). The concentration of the released 
solution was measured using an ultraviolet–visible absorbance 
spectrum (Figure 2b-ii, and Figure S3a,b, Supporting Infor-
mation). As a result, we validated that the released amount of 
drug was linearly proportional to the initial loading amount 
(Figure 2b-iii, and Figure S3c, Supporting Information). There-
fore, once the releasing ratios of the drugs were examined, 
we could easily modulate the target concentration by control-
ling the loading amount of the drugs (Table S1, Supporting 
Information).
For the cell-based assay, cells were seeded on the “cell chip” 
that has microwells with a diameter of 600 µm and a depth of 
350 µm. The gravitational settling method or the sealing film-
assisted seeding method was used for cell plating (Figure S4, 
Supporting Information). The sealing film-assisted seeding 
method was developed to reduce the number of cells required 
for the assay, which is applicable to rare cell screening, such 
as seeding stem cells or patient-derived cells (Figure S4b, Sup-
porting Information). Cell seeding on 1600 microwells was 
available only with 320 µL, which can fill only three microw-
ells on the 96-well plate. Here, the total volume of microwells 
is 160 µL, but two times more volume of cell suspension was 
used to fill all of the microwells without bubbles. This seeding 
method could be completed within 10 s, and the seeding uni-
formity was within 10% of the coefficient variation. After 
preparing the cell chip and drug-releasing hydrogel microarray-
on-a-chip, both chips were combined in a face-to-face manner 
to conduct multiplexed cell-based bioassays. Sequential treat-
ment assays were available by simply replacing the microarray-
on-a-chip after incubation.
Drug molecules in hydrogel microparticles start to dif-
fuse out after a microparticle touches a cell culture medium. 
During the incubation, each microwell should be completely 
isolated to prevent cross-contamination. This diffusion was 
validated with rhodamine-B (Figure 2c). The impregnated 
molecules in the microparticle were gradually released into 
the surrounding solution, and the releasing process was com-
pleted within ≈30–60 min (Figure 2c-i,ii). We also ensured that 
the isolation of each microwell was maintained perfectly for 
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at least 1 d (Figure 2c-iii). If the releasing speed was too fast, 
cross-contamination between microwells would occur during 
the chip assembly process, which requires ≈5 s. In contrast, if 
the releasing speed were too slow to finish the releasing pro-
cess within the drug incubation time, it would be difficult to 
obtain accurate assay results. Considering that the incubation 
time for an anticancer drug assay is usually more than 10 h, 
the releasing speed of our DLPs is acceptable for use in drug 
screening. Conversely, the sealing of microwells may inhibit gas 
exchange during the incubation period, which could affect the 
cell status. To understand this potential impact, we investigated 
the influence of sealing the cells in terms of cell morphology 
and viability, and there was neither a morphological change 
nor a decrease in the survival rate due to sealing (Figure S5, 
Supporting Information).
2.3. Decoding Process and Distribution of Sequential  
Combinatorial Codes
To identify which sequential combination of drugs was treated 
on each microwell from randomly assembled DLPs, we utilized 
encoded microparticles and developed automatic code-reading 
software (Figure 3a,b). Three code elements were used to con-
struct the graphical barcode (Figure 3a-i). The “long code” and 
“short code” were utilized to analyze the rotation angle and 
the upside-down inversion of a microparticle, respectively. 
After aligning the direction of a microparticle using long code 
and short code, the code of a microparticle is determined 
according to the location of “code circles” (Figure S6a,b, Sup-
porting Information). Without long code and short code, it is 
not possible to know whether the particle is rotated or flipped, 
and therefore, different codes that have the same relative posi-
tion between code circles cannot be distinguished (Figure S6c, 
Supporting Information). For the reading process, the detected 
particle image was transformed into polar coordinates first, and 
the positions of the code circles and the long code were rec-
ognized in the scanning window traversing the scanning line 
(Figure 3a-ii). To avoid a decoding error caused by the trunca-
tion of coding components, polar transformation was con-
ducted for 405° (360° and additional 45°) along the theta axis. 
A short code can be detected easily by comparing the intensity 
of the area at −90° and +90° from the long code position (θ). 
Finally, the code of the particle was determined according to 
the relative location between the coding components. By using 
neural-network-based image recognition and subsequent error-
correction procedure, more than 95% of the particles were suc-
cessfully decoded. The error under the 5% includes the broken 
particles whose code cannot be decoded. Finally, a sequential 
combinatorial code map was constructed by combining the 
code maps of the first and second chips (Figure 3b).
Because DLPs are randomly assembled into microwells, 
an important evaluation point regarding the feasibility of our 
platform is whether sufficient duplication numbers are guar-
anteed for all combinations. We carried out statistical analysis 
to answer this question. The assembly yield was 80.79%, and 
a binomial distribution was used to calculate the theoretical 
probabilities of combinations of code distributions. First, we 
Adv. Sci. 2018, 1801380
Figure 2. Drug delivery into the microwell using a microparticle. a) The loading uniformity of the freeze-drying-based loading method. Rhodamine-B 
was used as a model substance, and the fluorescence intensity was measured to estimate the loading amount of molecules. The loading uniformity was 
significantly improved compared to a conventional drug loading method (see also Figure S2, Supporting Information). Scale bar: 500 µm. b) Measuring 
drug releasing ratio. (i) The releasing ratio of each drug was measured from a bulk-scale releasing experiment. After drug loading by freeze-drying, 
1.5 mL of PBS was added to the DLPs. The concentration of released solution was measured after the overnight releasing process. (ii, iii) The UV–vis 
absorbance spectrum was used to measure the concentration of released solution. For all drugs, released amounts of drugs were linearly proportional 
to the initial loading amount (see also Figure S3 and Table S1, Supporting Information). Data of erlotinib and mitoxantrone are shown as representa-
tives. c) Drug releasing into microwells and isolation of each microwell during incubation. (i) Image of a microwell with Rhodamine-B releasing micro-
particle. Scale bar: 150 µm. (ii) Fluorescence intensity from a microparticle from time-lapse imaging shows that the releasing process was completed 
within 30–60 min. (iii) The isolation of each microwell was maintained over the 24 h incubation time. Scale bar: 1 mm.
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examined the probabilities with 45 sequential combinations, 
which were used for the screening that is demonstrated in the 
final section of this paper. The probabilities that a “specific” 
combination has a minimum duplication number (n) according 
to the number of microwells are represented (Figure 3c-i). 
However, to guarantee the minimum duplication numbers for 
“all” combinations, a different probability model is required. 
When microparticles are assembled in a limited number of 
microwells once the duplication number of a specific combina-
tion is determined, the probabilities of the remaining combi-
nations should be calculated under the number of remaining 
microwells (see also the Supporting Information). Such a 
probability of guaranteeing the minimum duplication number 
for all combinations can be modeled numerically with the 
Monte Carlo method (Figure 3c-ii). The probability was almost 
1.0 until the minimum guaranteed duplication number was 
15, and one example of an actual distribution of sequential 
combinatorial codes showed results that matched the simula-
tion result (Figure 3d). Next, we examined how many sequen-
tial drug combinations could be screened in a single chip 
(1600 microwells) to ensure a certain number of duplications 
(Figure 3e). Red-to-blue colors represent the probability that 
partipetting guarantees a duplication number greater than n (in 
each inset). Each white dashed line represents the maximum 
library size that is available in the situation that all drugs are 
conveyed to the decided position of a microwell with a con-
ventional liquid handling technique, which is not dependent 
on random assembly. There is a considerable difference in the 
Adv. Sci. 2018, 1801380
Figure 3. The automatic decoding and statistical analysis of code distributions. a) Decoding algorithm. (i) “Long code,” “short code,” and “code 
circles” are components for identifying the rotation, inversion, and code number of microparticles, respectively. Scale bar: 30 µm. (ii)–(iv) Particle 
image is transformed into polar coordinates, and the locations of each code component are recognized by a machine-learning-based algorithm. 
b) Construction of sequential combinatorial code map. Decoding results from all images are collected, and a sequential combinatorial code map is gen-
erated. c) Probability about the minimum duplication number. (i) Probabilities that a “specific” combination has a duplicate greater than n according 
to the number of microwells. (ii) Probability that “all” combinations will be found over a certain number of duplicates in 1600 microwells. d) Example 
of combinatorial code distribution. First and second drug libraries contain four and eight kinds of drugs, respectively. Total 45 combinations (including 
single or no drug treatment, represented by blue dots) were found from 1600 microwells. Red line (n = 32) is the expected value except for the cases 
in which no particle is applied in the second treatment (blue dots). e) Available library size for sequential combination screening in a single chip 
(1600 microwells). Color represents the probability of partipetting to guarantee that all combinations have duplications greater than n. White dashed 
lines are available library size for conventional pipetting technique.
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number of screenable drugs between our platform and that of 
the conventional platform for small n (i.e., n = 3). This is an 
inevitable drawback of our platform in implementing pipet-
ting-free HTS based on the random assembly of microparti-
cles. However, if the desired number of duplications is large 
enough (i.e., n = 15), the difference between the library sizes 
of screenable drugs for partipetting and conventional technolo-
gies is negligible. Since it is common to obtain a large number 
of duplicates to increase the accuracy on a miniaturized HTS 
platform that uses a small cell number, we consider that this 
shortage of our platform is not serious enough to diminish the 
advantage of using our platform, which can dramatically reduce 
the workload for large-scale bioassays. For a limited number 
of cells, such as patient-derived primary cells, the proposed 
platform can test many more drug candidates compared with 
that of conventional screening platforms (Table S3, Supporting 
Information).
2.4. Easy-to-Use Platform and Polystyrene Chip Fabrication
Soft lithography using PDMS traditional manufacturing technolo-
gies for microwells is useful for prototyping, but it is too expensive 
and slow for mass production.[29] Additionally, it is hard to conduct 
precise chip-to-chip aligning processes between two combined 
microwell arrays due to the flexible and stretchable characteristics 
of PDMS. Thus, we fabricated our platform with polystyrene (PS) 
chips by injection molding, which is an easily scalable strategy for 
rigid-plastic components with a 3D alignment key with pillar and 
hole structures to help perform sequential replacements easily 
(Figure 4a,b). However, PS chips can have a surface roughness 
on the micrometer-scale, and this roughness of the surface of PS 
chips is likely to create a slight gap between two combined chips, 
which may cause cross-contamination between adjacent micro-
wells. This cross-contamination could potentially lead to serious 
problems in microwell-based technology, since each microwell 
should perform a separated and isolated reaction. To ensure isola-
tion between adjacent microwells to prevent a cross-contamination 
problem, we devised a new chip called the transfer chip, which 
has a two-layered structure, with an elastic PDMS sheet on top of 
the rigid PS chip (Figure 4b-ii,c-i). If the rigid PS chip were used 
solely, it would be hard to prevent cross-contamination, because it 
is difficult to fabricate a plastic chip with uniform roughness in a 
micrometer-scale. This soft and elastic PDMS layer can help pre-
vent the problem by filling the gap between two plastic chips after 
two plastic chips were combined. For the stamping of DLPs array, 
the attraction force between the PDMS and microparticles made 
of PEGDA (Mn = 700) was strong enough to achieve a transfer 
yield of more than 99% and maintain adhesion after 1 d of incuba-
tion. There is no need for further surface treatment on the PDMS 
layer, and the stamping of the DLPs array could be conducted with 
only finger pressure. By carefully controlling some parameters, 
such as the depth and diameter of each microwell and the distance 
between adjacent microwells, we manufactured a set of large-
scale PS chips that can perform 1600 parallel reactions within a 
52 mm × 52 mm area.
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Figure 4. A polystyrene (PS) chip system fabricated by injection molding and a multipurpose holder for easy alignment. a) PS chip system with 
1600 microwells and universal holder for alignment. b) Images of chip components. (i) Cell chip and transfer chip (hydrogel microarray-on-a-chip) 
are combined with the help of holes on the cell chip and pillars on the transfer chip. (ii) A two-layer system composed of a PDMS sheet on the PS 
chip was applied to the transfer chip. Rigid PS body with pillars enables the simple alignment of a hydrogel microarray on a target cell chip, and an 
elastic PDMS sheet facilitates complete sealing between the cell chip and transfer chip (microarray-on-chip). (iii, iv) Universal holder was designed to 
assist alignment between the assembly chip and transfer chip and imaging on the microscope at a predefined position. c) Schematic illustration of 
experimental procedure. (i, ii) DLP array on the assembly chip is transferred to the transfer chip with the aid of the universal holder. (iii) The hydrogel 
microarray-on-chip and cell chip are combined through a 3D alignment key composed of pillars/holes. (iv) Universal holder helps to locate the cell 
chip and assembly chip in a predefined position on the microscope.
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A schematic illustration of how each chip and the universal 
holder is used in each step is shown in the experimental order 
(Figure 4c). Assembled DLPs on the assembly chip are trans-
ferred to the transfer chip with the help of a multipurpose 
plastic holder (named a “universal holder”) for exact alignment. 
Then, large-scaled imaging for positional code mapping is per-
formed. The imaging process is implemented on the universal 
holder, which is designed to be the same size and is compat-
ible with the microscopic stage for conventional 96-well plates; 
thus, all the microparticles are located at preset coordinates. 
Subsequently, combining the transfer chip (microarray-on-a-
chip) and the cell chip induces drug release. In this process, 
pillars on the transfer chip and holes in the cell chip facilitate 
an exact alignment. After incubation, whole microwells on 
the cell chip with drug-treated cells are imaged on the top of the 
universal holder, thereby collecting viability information on the 
whole chip.
2.5. Multiplexed Sequential Drug Combination Assay
We previously validated the availability of the partipetting plat-
form to screen concurrent combinatorial drugs by control-
ling the design of the placement of microwell arrays on the 
assembly chip.[26] However, the previous version of our platform 
could support only a single incubation step. In this work, we 
demonstrated a sequential combination assay with the concept 
of exchanging a drug-releasing hydrogel microarray-on-a-chip. 
This becomes available with the advantages of the 3D-align key 
on rigid plastic chips. For the proof-of-concept, a sequential cell 
staining assay was first demonstrated by using cytosol staining 
with green and orange CellTracker dyes followed by nucleus 
staining with blue Hoechst 33342 and green SYTO 16 nucleic 
acid staining dyes (Figure 5). Two drug-releasing hydrogel 
microarrays-on-a-chip were combined sequentially on one cell 
chip. Hydrogel microarray-releasing cytosol-staining dyes and 
nucleus-staining dyes were placed on the first and second chips, 
respectively. It was confirmed that the fluorescence images of 
the cells were clearly distinguished depending on the combina-
tion of staining dyes treated sequentially (Figure 5a). In total, 
nine combinations were possible by using staining dyes, and 
we could find all of them from the images of the microwells on 
the cell chip (Figure 5b). For a large-scale experiment, a sequen-
tial combination staining experiment was conducted on a large-
scale chip with 1600 microwells (Figure 5c). From these results, 
we validated that the sequential delivery of drugs to each iso-
lated microwell is available in a scalable manner by exchanging 
a hydrogel microarray-on-a-chip.
Finally, we applied the proposed platform to conduct large-
scale screening of the anticancer efficacy of sequential drug 
combinations (EGF receptor inhibitor followed by a DNA 
damaging agent) against the triple-negative BT-20 cell line 
(Figure 6). TNBC has remained an aggressive cancer without 
effective single-targeted therapies, thus trials of treating 
patients with combinatorial drugs are being administered 
widely.[30] The list of screened drug combinations is shown 
in Figure 6a and in Table S1 (Supporting Information). In 
the experiments, the final concentration of all drugs released 
from DLP was adjusted to 10 × 10−6 m (Table S1, Supporting 
Information), and each sequential drug was incubated for 12 h 
with inhibitory drugs and 10 h with the DNA damaging agents 
(time-table shown in Figure S7, Supporting Information). For 
all combinations, the experimental results from 96-well plates 
and our platform had similar drug efficacies (Figure 6c). The 
cytotoxicity of single-drug therapies and the sequential treat-
ment from one combination, erlotinib and doxorubicin (indi-
cated as a black box in Figure 6c), are represented in the bar 
graph (Figure 6b). Although our platform has a higher CV value 
(≈15%) than that of the 96-well platform (≈3%), it is a trade-off 
caused by the small reaction volume and fewer cell numbers. 
From the screening results, erlotinib followed by mitoxantrone 
was revealed to be the most effective sequential pair among the 
total 45 combinations. The survival rate of cells treated with 
this pair was 44.46% in experiments using our platform and 
40.63% in 96-well plate experiments. To evaluate the synergism 
of the combination, a dose–response matrix was also obtained 
using our platform (Figure 6d). All of the results from the pro-
posed platform were within ±15% of those obtained by using a 
conventional approach, which proved the feasibility of our plat-
form for sequential drug combination assays.
3. Discussion
In this study, we described a large-scale screening platform 
to find effective sequential drug combinations. The delivery 
of encoded drug-laden microparticles using one-step pipet-
ting and the self-assembly of these microparticles to an array 
of microwells can replace thousands of pipetting operations. 
For a multistep drug incubation, only a simple exchange of the 
hydrogel microarray-on-a-chip is required instead of repeating 
thousands of pipetting operations for every treatment step. 
Furthermore, since our platform supports the screening of 
concurrent combinatorial drugs, this technique can apply to 
the various forms of combination screening. Such a significant 
decrease in the workload would give hospitals and laboratories 
with limited resources the opportunity to perform large-scale, 
multistep bioassays at an affordable cost and within a reason-
able timeframe. Regarding the required number of samples, 
only 200 cells per microwell were needed, and the uniform 
seeding of 1600 microwells was possible without a robotic 
pipette machine through the sealing film-assisted seeding 
method. To make this platform usable by other researchers, we 
designed an easy-to-use platform by introducing 3D pillar/hole 
structures and a multipurpose holder for easy alignment.
It has not been long since researchers discovered that the 
effects of sequential combinations can be attributed to the 
dynamics of signaling pathways. Therefore, there are many 
opportunities for new achievements, as our biological under-
standing of disease deepens. We envision that personalized 
screening results from sequential combinations will help deter-
mine drug schedules for each patient.[14,17] In addition, our 
platform for multistep combinatorial screening can potentially 
be applied in other research fields, such as the differentia-
tion and reprogramming of various cell types,[24,31–34] the per-
formance of drug screening using cells transduced with various 
viral vectors,[35,36] or the creation of personalized drug sched-
uling using patient-derived cell lines. We expect that multistep, 
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large-scale screening using partipetting will be more accessible 
to researchers in a wide range of fields, thereby broadening the 
applications of high-throughput, sequence-dependent combina-
torial bioassays.
4. Experimental Section
Encoded Microparticle Fabrication: Encoded hydrogel microparticles 
were fabricated via UV photolithography (OmniCure S1500, Excelitas 
Technology Corp.) with poly(ethylene glycol)-diacrylate (PEGDA, 
Mn = 700; Sigma-Aldrich) and 5 wt% photoinitiator (2-hydroxy-2-
methylpropiophenone 97%, Sigma-Aldrich). To generate different codes 
for each hydrogel microparticle, different masks (MicroTech, South 
Korea) with the capacity to generate 15 225 microparticles at once were 
used. All of the fabricated hydrogel particles were first collected in an 
ethyl alcohol (EtOH) solution. To prevent the photoinitiator residue of 
uncured resin from damaging cells, the washing steps with fresh EtOH 
solution were repeated two times, and then dried. Here, the photomask 
for making microparticles of a diameter 150 µm was used, but the 
fabricated microparticle slightly shrinks to 138 µm diameter after drying. 
However, all of the coding components shrunk at the same rate while 
maintaining their shape; thus, there was no problem in reading the code.
Chip Fabrication: All of the plastic chips, including the assembly chip, 
transfer chip, and cell chip, were manufactured by plastic injection 
molding using an injection mold (Woojin Selex Co., Ltd., South Korea). 
An aluminum mold was made using a CNC milling machine (Hwacheon 
Technology, South Korea). All of the chips, which were made of 
polystyrene (GPPS, LGChem, South Korea), contained 1600 microwells. 
The microwells of the cell chip had a diameter of 0.6 mm and a well-
to-well distance of 1.5 mm. The microwells on the assembly chip had 
a diameter of 160 µm and a well-to-well distance of 1.5 mm (the same 
distance as the wells on the cell chip).
Preparation of DLPs and Measuring Drug-Releasing Ratio: Erlotinib 
hydrochloride and gefitinib (free base) were purchased from LC 
Laboratories, and all of the other chemical drugs were purchased 
from Sigma Aldrich. The drug concentration was measured with an 
ultraviolet–visible spectrophotometer (UV-1800, Shimadzu). First, the 
peak wavelength of absorbance spectrum was measured for each drug 
(Figure 2b-ii, and Figure S3a, Supporting Information). Subsequently, a 
reference curve for the relationship between the drug concentration and 
corresponding absorbance peak was obtained by using samples with 
a known concentration (Figure S3b, Supporting Information). Then, 
the concentrations of the unknown samples can be calculated from the 
reference curve (Figure S3c, Supporting Information). To evaluate 
the drug-releasing ratio of each drug, the following procedure was 
conducted. First, drug solution (dissolved in 25 µL dimethyl sulfoxide 
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Figure 5. Sequential combinatorial cell staining. a) Schematic illustration of the staining process, and magnified images of stained cells. Cell Tracker 
(CT) green and orange were used for the first staining, and Syto 16 (green) and Hoechst (Hst) 33342 (blue) were used for the second staining. Scale 
bar: 50 µm. b) All possible combinations of sequential staining. In total, nine combinations were found on the whole chip, including the case in which 
staining dyes were not treated. Scale bar: 150 µm. c) Staining image of the whole chip with 1600 microwells. Scale bar: 5 mm.
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(DMSO)) at a known concentration was added to 15 225 microparticles, 
which were fabricated from a single mask. After freeze-drying, PBS 
solution (1.5 mL) was added to drug-laden microparticles, and then 
the mixture was shaken on a mixing block (MB-102, BIOER) overnight, 
which was enough time for complete release. Next, the concentration of 
the released solution was measured. The particle number (15 225) to the 
releasing volume (1.5 mL) ratio was equivalent to the ratio of a single 
particle to the volume of one microwell (100 nL) (Table S2, Supporting 
Information). It was tried to eliminate the differences in the releasing 
ratios that might occur depending on the particle numbers and volume 
ratios. Five data points for each drug were collected (see also Figure 2, 
Figure S3 and Table S1, Supporting Information).
Cell Culture: BT-20 human mammary gland/breast carcinoma cells 
(ATCC) and U2OS human osteosarcoma cells (KCLB, Korean Cell Line 
Bank) were cultured in Eagle’s minimum essential medium (EMEM) 
and McCoy’s 5A culture medium, respectively. Both media were 
supplemented with 1% penicillin-streptomycin and 10% fetal bovine 
serum (at 37 °C under 5% CO2 and 95% atmospheric air). Cultured cells 
were trypsinized to detach them from the culture flask by using 0.25% 
trypsin and 0.13% EDTA in phosphate-buffered saline. The cells were 
centrifuged and dispersed in the cell culture medium. All of the plastic 
chips were sterilized with EtOH sonication, oven dried at 60 °C, and 
given oxygen plasma treatment for 4 min.
Sequential Cell Staining: To demonstrate heterogeneous sequential 
cell staining, green and orange CellTracker (0.25 × 10−3 m, 25 µL, 
Invitrogen) were loaded into the microparticles for cytosol staining. For 
the second staining, Hoechst 33342 (blue, 0.05 × 10−3 m, 25 µL) and 
SYTO 16 (green, 0.05 × 10−3 m, 25 µL, Invitrogen) were loaded into 
the microparticles for nucleus staining. The incubation time for each 
staining step was 4 h.
Cell Viability Assay: For the cell viability assay, Calcein AM (Thermo 
Fisher Scientific) was used to stain the live cells. ≈1 mg mL−1 Calcein 
AM solution was diluted in serum-free EMEM culture media at a 1:1000 
ratio, and the cells were incubated with the solution for 30 min. After 
PBS washing, fluorescence images of the microwells on a cell chip 
were obtained by using a microscope setup with a motorized stage 
(Nikon Digital Sight DS-Ri1, Nikon C-LHGFI HG LAMP). A fluorescein 
isothiocyanate (FITC) channel filter (excitation 490 nm, emission 
525 nm) with an exposure time of 200 ms for a 2× objective lens or 
60 ms for 4× lens were used for image acquisition. The viability was 
decided by relative pixel intensity from the fluorescence image of a 
microwell area compared with that of nondrug-treated microwells (the 
control). For the average viability of each drug combination, 10% of the 
upper and lower value data were excluded as outliers.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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